Jamie Weisman

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Allergy, Atopic Dermatitis, Allergy Medicine +8

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried et al. · JAMA Dermatology · 2019 · 479 citations · Full text

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi et al. · Journal of the American Academy of Dermatology · 2020 · 363 citations · Full text

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Christos C. Zouboulis, Martin M. Okun, Errol P. Prens et al. · Journal of the American Academy of Dermatology · 2018 · 182 citations

Long-term Adalimumab Efficacy, Autoimmune Disease, Open-label Extension Study +6

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Satveer K. Mahil, Nick Dand, K.J. Mason et al. · Journal of Allergy and Clinical Immunology · 2020 · 158 citations · Full text

Adverse Covid-19 Outcomes, Global Health, Covid-19 Pandemic +9